Product Description |
Recombinant Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein is expressed from E.coli with with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide. |
Product Background |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
Product Category |
Recombinant Protein |
Target |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer |
MHC Form |
Monomer |
Allele |
HLA-A*11:01 |
Accession |
|
Species |
Human |
Biotinylated |
no |
Amino Acid Range |
Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide |
Molecular Weight |
The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result. |
Activity |
Immobilized HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 5ug/ml (100ul/well) on the plate. Dose response curve for Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag with the EC50 of 66.0ng/ml determined by ELISA (QC Test). The affinity constant of 6.93 nM as determined in SPR assay (Biacore T200). See testing image for detail. |
Product Tag |
C-His-Avi |
Express System |
E.coli |
Purity |
> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC |
Endotoxin |
Less than 1EU per ug by the LAL method. |
Form |
Lyophilized |
Shipping |
Shipped at ambient temperature. |
Formulation |
Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Stability And Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
|
Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag captured on CM5 Chip via anti-his antibody can bind HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR with an affinity constant of 6.93 nM as determined in SPR assay (Biacore T200). |
|
|
Immobilized HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 5ug/ml (100ul/well) on the plate. Dose response curve for Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag with the EC50 of 66.0ng/ml determined by ELISA (QC Test). |
|
|
Immobilized Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 9.1ng/ml determined by ELISA. |
|
|
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. |
|
|
The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer is greater than 95% as determined by SEC-HPLC. |
Product Resources
Related Products
Have more questions?
Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.
Contact Us
Recently viewed
